Published in Mol Ther on September 09, 2008
Progress toward in vivo use of siRNAs-II. Mol Ther (2011) 1.60
Quantitative evaluation of siRNA delivery in vivo. RNA (2010) 1.03
Integrin signaling aberrations in prostate cancer. Am J Transl Res (2009) 1.01
Slow disease progression in a C57BL/6 pten-deficient mouse model of prostate cancer. Am J Pathol (2011) 1.01
Noninvasive imaging of lipid nanoparticle-mediated systemic delivery of small-interfering RNA to the liver. Mol Ther (2010) 0.96
Efficient Biodistribution and Gene Silencing in the Lung epithelium via Intravenous Liposomal Delivery of siRNA. Mol Ther Nucleic Acids (2013) 0.86
Low-Molecular-Weight Polyethyleneimine Grafted Polythiophene for Efficient siRNA Delivery. Biomed Res Int (2015) 0.77
Development of a Positive-readout Mouse Model of siRNA Pharmacodynamics. Mol Ther Nucleic Acids (2013) 0.76
Critical role of NKT cells in posttransplant alloantibody production. Am J Transplant (2014) 0.76
Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet (1999) 55.63
Promoter traps in embryonic stem cells: a genetic screen to identify and mutate developmental genes in mice. Genes Dev (1991) 13.28
Disruption of overlapping transcripts in the ROSA beta geo 26 gene trap strain leads to widespread expression of beta-galactosidase in mouse embryos and hematopoietic cells. Proc Natl Acad Sci U S A (1997) 8.35
RNAi-mediated gene silencing in non-human primates. Nature (2006) 7.60
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol (2008) 6.81
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol (2005) 6.40
Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov (2007) 6.37
Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol (2006) 6.30
Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev (2001) 4.47
Shifting foci of hematopoiesis during reconstitution from single stem cells. Proc Natl Acad Sci U S A (2003) 4.41
Molecular imaging in drug development. Nat Rev Drug Discov (2008) 4.06
Visualizing gene expression in living mammals using a bioluminescent reporter. Photochem Photobiol (1997) 3.47
Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci U S A (2005) 3.24
Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia (2001) 2.97
Noninvasive optical imaging of firefly luciferase reporter gene expression in skeletal muscles of living mice. Mol Ther (2001) 2.96
Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood (2002) 2.79
Visualizing the kinetics of tumor-cell clearance in living animals. Proc Natl Acad Sci U S A (1999) 2.76
In vivo imaging of NF-kappa B activity. J Immunol (2002) 2.36
Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2'-deoxycytidine analog. Nat Med (2008) 2.24
Real-time imaging of ligand-induced IKK activation in intact cells and in living mice. Nat Methods (2005) 2.22
Mouse reporter strain for noninvasive bioluminescent imaging of cells that have undergone Cre-mediated recombination. Mol Imaging (2003) 2.17
In vivo imaging using bioluminescence: a tool for probing graft-versus-host disease. Nat Rev Immunol (2006) 2.06
Photic and circadian expression of luciferase in mPeriod1-luc transgenic mice invivo. Proc Natl Acad Sci U S A (2001) 1.96
Noninvasive real-time imaging of apoptosis. Proc Natl Acad Sci U S A (2002) 1.93
Molecular imaging using labeled donor tissues reveals patterns of engraftment, rejection, and survival in transplantation. Transplantation (2005) 1.82
Noninvasive imaging of protein-protein interactions in living animals. Proc Natl Acad Sci U S A (2002) 1.81
Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature (2007) 1.66
Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. Proc Natl Acad Sci U S A (1997) 1.47
Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res (2007) 1.33
Monitoring the trafficking of adoptively transferred antigen- specific CD8-positive T cells in vivo, using noninvasive luminescence imaging. Hum Gene Ther (2007) 1.23
The generation of a conditional reporter that enables bioluminescence imaging of Cre/loxP-dependent tumorigenesis in mice. Cancer Res (2003) 1.19
Understanding immune cell trafficking patterns via in vivo bioluminescence imaging. J Cell Biochem Suppl (2002) 1.07
Chemotherapeutic agents up-regulate the cytomegalovirus promoter: implications for bioluminescence imaging of tumor response to therapy. Cancer Res (2007) 1.05
Non-invasive imaging of dendritic cell migration in vivo. Immunobiology (2006) 0.90
Bioluminescence detection of cells having stabilized p53 in response to a genotoxic event. Mol Imaging (2004) 0.87
Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol (2007) 17.80
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature (2004) 12.75
Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov (2009) 12.46
Engineering vascularized skeletal muscle tissue. Nat Biotechnol (2005) 7.73
RNAi-mediated gene silencing in non-human primates. Nature (2006) 7.60
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A (2006) 6.90
Impact of nanotechnology on drug delivery. ACS Nano (2009) 6.87
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol (2008) 6.81
Microscale technologies for tissue engineering and biology. Proc Natl Acad Sci U S A (2006) 6.66
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med (2012) 5.92
Nanoliter-scale synthesis of arrayed biomaterials and application to human embryonic stem cells. Nat Biotechnol (2004) 5.51
Transdermal drug delivery. Nat Biotechnol (2008) 5.11
Rational design of cationic lipids for siRNA delivery. Nat Biotechnol (2010) 4.97
Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci U S A (2002) 4.77
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A (2008) 4.57
Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res (2004) 4.56
Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol (2005) 4.55
Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol (2008) 4.46
Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol (2005) 4.44
A tough biodegradable elastomer. Nat Biotechnol (2002) 4.35
Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci U S A (2010) 4.25
Functional assembly of engineered myocardium by electrical stimulation of cardiac myocytes cultured on scaffolds. Proc Natl Acad Sci U S A (2004) 4.13
Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials (2006) 4.09
Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J Gene Med (2005) 4.04
Accordion-like honeycombs for tissue engineering of cardiac anisotropy. Nat Mater (2008) 4.00
A reversibly switching surface. Science (2003) 3.97
Deletion of brain dystroglycan recapitulates aspects of congenital muscular dystrophy. Nature (2002) 3.96
Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol (2011) 3.95
Small-scale systems for in vivo drug delivery. Nat Biotechnol (2003) 3.90
Small-molecule modulators of Hedgehog signaling: identification and characterization of Smoothened agonists and antagonists. J Biol (2002) 3.85
Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A (2008) 3.80
Nanoparticle delivery of cancer drugs. Annu Rev Med (2011) 3.75
Endothelial cells derived from human embryonic stem cells. Proc Natl Acad Sci U S A (2002) 3.66
Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A (2008) 3.62
First-in-human testing of a wirelessly controlled drug delivery microchip. Sci Transl Med (2012) 3.56
Controlled degradation and mechanical behavior of photopolymerized hyaluronic acid networks. Biomacromolecules (2005) 3.44
Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov (2004) 3.41
Oncomodulin is a macrophage-derived signal for axon regeneration in retinal ganglion cells. Nat Neurosci (2006) 3.35
Functional recovery following traumatic spinal cord injury mediated by a unique polymer scaffold seeded with neural stem cells. Proc Natl Acad Sci U S A (2002) 3.35
MIFlowCyt: the minimum information about a Flow Cytometry Experiment. Cytometry A (2008) 3.33
Treating metastatic cancer with nanotechnology. Nat Rev Cancer (2011) 3.30
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther (2010) 3.26
Hyaluronic acid hydrogel for controlled self-renewal and differentiation of human embryonic stem cells. Proc Natl Acad Sci U S A (2007) 3.19
Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med (2008) 3.16
Nanotechnological strategies for engineering complex tissues. Nat Nanotechnol (2010) 3.15
Combinatorial development of biomaterials for clonal growth of human pluripotent stem cells. Nat Mater (2010) 3.11
Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat Nanotechnol (2012) 3.09
Engineering substrate topography at the micro- and nanoscale to control cell function. Angew Chem Int Ed Engl (2009) 3.09
Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol (2012) 3.01
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov (2013) 2.88
Microengineered hydrogels for tissue engineering. Biomaterials (2007) 2.87
Differentiation of human embryonic stem cells on three-dimensional polymer scaffolds. Proc Natl Acad Sci U S A (2003) 2.86
Semi-automated synthesis and screening of a large library of degradable cationic polymers for gene delivery. Angew Chem Int Ed Engl (2003) 2.83
Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol (2013) 2.81
The inflammatory responses to silk films in vitro and in vivo. Biomaterials (2005) 2.79
Biodegradable, elastic shape-memory polymers for potential biomedical applications. Science (2002) 2.79
Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano (2008) 2.76
Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev (2006) 2.69
Multi-pulse drug delivery from a resorbable polymeric microchip device. Nat Mater (2003) 2.65
A combinatorial polymer library approach yields insight into nonviral gene delivery. Acc Chem Res (2008) 2.63
A biodegradable and biocompatible gecko-inspired tissue adhesive. Proc Natl Acad Sci U S A (2008) 2.58
Macroporous nanowire nanoelectronic scaffolds for synthetic tissues. Nat Mater (2012) 2.57
Light-induced shape-memory polymers. Nature (2005) 2.52
Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: the Women's Health Initiative Observational Study. Circulation (2005) 2.49
Medium perfusion enables engineering of compact and contractile cardiac tissue. Am J Physiol Heart Circ Physiol (2003) 2.42
Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci U S A (2012) 2.42
Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett (2007) 2.40
A vector-free microfluidic platform for intracellular delivery. Proc Natl Acad Sci U S A (2013) 2.40
Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol Ther (2009) 2.39
An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed Engl (2006) 2.38
Bio-inspired polymer composite actuator and generator driven by water gradients. Science (2013) 2.38
Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett (2010) 2.35
Controlling size, shape and homogeneity of embryoid bodies using poly(ethylene glycol) microwells. Lab Chip (2007) 2.30
Biocompatibility and biofouling of MEMS drug delivery devices. Biomaterials (2003) 2.27
Bone tissue engineering using human mesenchymal stem cells: effects of scaffold material and medium flow. Ann Biomed Eng (2004) 2.26
Endothelialized microvasculature based on a biodegradable elastomer. Tissue Eng (2005) 2.23
Silk implants for the healing of critical size bone defects. Bone (2005) 2.22
PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials (2008) 2.21